| INTRODUC TI ON
Overall survival (OS) in adult acute lymphoblastic leukaemia (ALL) has improved over the last decades. A population-based study from the Netherlands with patients with ALL diagnosed from 1989 to 2012 revealed improved survival for all patients younger than 70 years. 1 The 5-year OS was 75% for patients 18-24 years but only 37% for patients between 40 and 59 years in recent years, a finding confirmed by others. [2] [3] [4] [5] The improvement in OS seen in younger adults (predominantly in Philadelphia-negative [Ph-neg] ALL) has been connected to the introduction of paediatric-inspired protocols with multidrug induction, high-dose methotrexate and asparaginase, as well as risk-adapted treatment according to disease-and response-related factors. 1, 6, 7 The toxicity profile has been found acceptable, at least to the age of 45 years. 6, 8, 9 Later reports indicate that age-adapted paediatric-inspired therapy is feasible up to the age of 65 years. 10 In Philadelphiapositive (Ph-pos) ALL, the introduction of tyrosine kinase inhibitors (TKI) has fundamentally changed clinical practice and rendered improved OS both with and without allogeneic hematopoietic stem cell transplantation (HSCT). 5, [11] [12] [13] [14] [15] Taken together, there is convincing evidence of therapeutic advancements in the last decades. However, there is lack of knowledge on ALL outcome from population-based studies that include information about Ph-pos disease and allogeneic HSCT.
We used the nationwide Swedish Acute Leukaemia Registry, later the Swedish ALL Registry, to investigate disease characteristics, treatment and survival in patients diagnosed with ALL between 1997 and 2015.
| PATIENTS AND ME THODS

| The Acute Lymphoblastic Leukaemia Registry
Since 1958, both pathologists and clinicians are obliged to report every cancer at diagnose to the Swedish Cancer Registry. The dual reporting system improves coverage and accuracy. From the Cancer Registry, diagnosis-specific quality registries have evolved.
From 1997, patients with acute leukaemia were monitored in the nationwide but regionally based Acute Leukaemia Registry. In 2007, the registry became a web-based system, divided into the Acute Myeloid Leukaemia (AML) Registry and the ALL Registry as part of the new centralised Blood Cancer Registry. The registry has been previously described in detail, and the first report on ALL incidence was published in 2010. [16] [17] [18] Different cohort studies have been performed with identification of patients from the ALL Registry, but an analysis of the complete registry has never been published. [19] [20] [21] Into the ALL Registry, the treating physicians prospectively re- The database for this study was merged from the "old" ALL Registry with some variables recoded to enable overall analysis.
Definitions are described in Data S1. Because some variables were only reported in the new registry, they were analysed solely for this period. No verification of the ALL diagnosis was done beyond the dual reporting system.
| Genetic analysis
Since 2007, Ph-pos disease was reported in the registry even though as early as 1997 Ph-pos leukaemia was considered a highrisk criterion in the national guidelines. The recommended methods of investigation were conventional cytogenetics, fluorescent in situ hybridization (FISH) and/or polymerase chain reaction (PCR).
In this study, the reported genetic analysis was validated and missing data were collected from the six central genetic laboratory facilities performing the analysis in Sweden. Patients not confirmed to be Ph-pos ALL are labelled Ph-neg ALL in this text-except when calculating Ph frequency and OS for B-ALL. In the latter two analyses, patients not adequately examined (defined as normal karyotype with ≥20 metaphases, another karyotype with clonal abnormality, a negative FISH or a negative PCR for major and minor transcript)
were considered to have missing data (details in Data S1).
| Treatment
Treatment recommendations, as part of national guidelines, changed over time (details in Data S1 and Table S1 ). In brief, the Swedish protocol ABCDV/VABA was the main remission-inducing protocol. 23 After a pilot study, patients 18-45 years with Ph-neg ALL were treated according to the paediatric NOPHO ALL 2008 protocol. 24 Hyper-CVAD was recommended for T-ALL cases between 2003 and 2009. 25 For patients with Burkitt leukaemia, the NHL-BFM-90
protocol and subsequently the GMALL-B-ALL/NHL2002 were advocated. 26, 27 For older patients, age-adopted protocols such as the EWALL-backbone were suggested. 15 Addition of imatinib to chemotherapy backbones for Ph-pos ALL was formally recommended in 2007 but was gradually introduced the years before.
| Statistics
Fischer's exact test was used to compare categorical variables. Excluding the one patient with Ph-pos T-ALL.
differences compared with the log-rank test. Univariable and multivariable Cox Regression analyses were used to determine hazard ratio (HR) of covariates included in the multivariable model. and conducted in accordance with the Declaration of Helsinki.
| RE SULTS
| Patients
We identified 937 patients 18 years or older diagnosed with ALL between 1997 and 2015. Three patients were excluded due to a known Philadelphia chromosome one, two and 6 years before ALL diagnosis as these patients were judged to have chronic myeloid leukaemia in lymphatic blast crisis. One patient was excluded because of a relapse of childhood leukaemia.
Patient characteristics of the remaining 933 patients are presented in Table 1 . The B-ALL cohort comprised 68%, T-ALL 15% and Burkitt leukaemia 4%. The group of ALL Not Otherwise Specified (NOS) diminished from 22% in the old to 5% in the new registry.
Median age at ALL diagnosis was 53 years (range 18-95 years)
and was similar for Ph-pos (53 years) and Ph-neg B-ALL (54 years).
As expected, the T-ALL cohort was younger (37 years) and mainly male. Burkitt and ALL NOS patients were significantly older (61 and 64 years) than the Ph-neg B-ALL. The WHO-PS was 0-1 in 73% of patients and 2 or more in 24%.
| Frequency of Philadelphia-positive ALL
Information about Ph-pos disease was reported only in the new reg- missing data, P = ns). In examined B-ALL (1997-2015), the incidence was 34% (n = 635 B-ALL; 167 Ph-pos, 331 Ph-neg and 137 with missing data). The Ph frequencies for different age cohorts are displayed in Figure 1 . The highest incidence (47%) was found in patients 50-59 years and did not increase further with age.
| Descriptive variables only reported in the new registry 2007-2015
The median white blood cell count (WBC) was higher in the Ph-pos cohort as well as in the T-ALL cohort compared with Ph-neg B-ALL (Table 1) 
| Treatment and outcome
Survival analyses were done with patients divided into three age groups (18-45, 46-65 and >65 years) and for two time periods (1997-2006 and 2007-2015) . Unless otherwise stated, comparisons between Ph-pos and Ph-neg ALL are done without further subgrouping.
| Remission intention and early deaths
Details are described in 
| Treatment intensity and complete remission
In the old registry, information about given treatment was restricted to (a) intensive/remission-inducing, (b) palliative chemotherapy or (c) no treatment/supportive care. In the new registry, more detailed information was collected (Table 2) . Of the patients with information about CR status and intention to treat into remission, 88% reached a CR1. In patients 18-45, 46-65 and >65 years, the CR rates were 97%, 89% and 70%, respectively (Table 2 ).
| Overall survival
Five-year OS improved in all age groups and increased from 50% When divided into Ph-neg and Ph-pos ALL, OS improved in all groups (P < 0.05 for pairwise comparison, log-rank) except for Phneg patients >65 years (P = ns, log-rank; Figure 3A and B). In Ph-pos ALL, only borderline significance was seen in patients 46-65 years (P = 0.05, log-rank; Figure 4A and B).
Five-year OS divided by phenotype and age group is presented in Table S2 .
The standardised mortality ratio (SMR) was 5.7 (95% CI 5.0-6.3)
for patients that had survived 5 years from diagnosis (SMR-the number of deaths in the study cohort compared to the age-ad- 
| Prognostic factors
To evaluate the impact of different variables on OS, univariable and multivariable analyses were done for the entire registry and for the later time period (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) and are presented in Table   S3 . [95% CI 35-52], P < 0.01, log-rank). The difference was present in both time periods, but subgroup analysis revealed that the difference was significant only in the Ph-neg B-ALL cohort (n = 130); 5-year OS for men was 20% (95% CI 9.7-30) and for women 52% (95% CI 40-64; P < 0.01, log-rank). Information about treatment and CR status was reported for 122 patients, and all but one received treatment with remission intention with a CR rate of 89% (85% for males and 93%
for females, P = ns). There were no significant differences between sexes regarding WHO-PS at diagnosis, median age, median WBC, 
| D ISCUSS I ON
To our knowledge, this is the largest population-based cohort presenting data on outcome in adult ALL including information about Ph-pos disease and allogeneic HSCT. [1] [2] [3] 5, 28 An important aspect of population-based studies is to provide aggregated clinical information that is less susceptible to the inherent selection bias of randomised controlled trials. In line with this, we present a higher median age of 53 years at ALL diagnosis and, in a study population without an upper age limit, that the median age did not differ between Ph-pos and Ph-neg B-ALL. [28] [29] [30] [31] As expected, T-ALL patients were younger and we can corroborate that Burkitt leukaemia/ mature B-ALL have a substantially higher median age (61 years) than other B-ALL. 28 We confirm a high frequency of Ph-pos dis-
ease-26% of all tested patients and 34% of B-ALL with a peak incidence in patients 50-59 years. This is a higher frequency of TA B L E 2 Treatment intention, early deaths and complete remission rates for the whole study period (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) Abbreviations: ALL, acute lymphoblastic leukaemia; CR, complete remission; Ph-pos, Philadelphia-positive; Ph-neg, Philadelphia-negative. a Four patients with missing data on remission intention, total n = 929. Three patients with missing data on the exact date of diagnosis, total n = 926. c Regimens reported; for references, see Data S1. d Instructions for registration of treatment has changed over time and the exact intensive therapy given has not always been possible to report.
Ph-pos ALL than suggested by the landmark study of Moorman et al 28 but comparable to Wetzler et al 32 and a more recent large Italian cohort study. 33 On the other hand, we did not find a continuous age-associated increase suggested in the Italian paper and by Secker-Wetzler et al 34 but these studies had an upper age limit of 60 years and a low overall Ph-pos frequency, respectively. Furthermore, the peak incidence of Ph-pos disease in the fifth decade with a plateau between 30-60 years is in line with
Moorman and the French trial from 1996. 30 Because of thoroughly testing in the latter period, we suggest that our data represent and approach the true incidence and age distribution of Ph-pos ALL in a northern European population.
In spite of a high median age in the total cohort, the intention to treat into remission was high (89%), especially in comparison with the 73% treated with curative intention in Denmark. 3 In younger patients, 99% received remission-inducing therapy, and in patients >65 years, the corresponding figure was 67%.
In Swedish AML patients, the attitude towards remission-inducing therapy in the elderly has been shown to influence overall survival. 16 Whether this applies to ALL has, to our knowledge, not been studied. However, the previously low testing for Ph-pos disease together with the 30-day mortality of 43% patients with palliative intention (median age 80 years) indicates that there is potential to improve outcome, especially in view of the possibility to use TKI in this patient group. 35 The improvement in OS in Ph-neg patients aged 18-45 years corresponds to the change to the use of paediatric protocols (NOPHO ALL 2008 proceeded by a pilot with NOPHO ALL 1992). For patients 46-65 years, a similar improvement was noted. We hypothesise that better supportive care, the addition of rituximab, older patients treated according to the paediatric protocols and the use of reduced intensity conditioning in allogeneic HSCT could have been beneficial. [36] [37] [38] For the elderly Ph-neg patients, no increase in OS was seen despite the introduction of an age-adapted protocol. 10, 21 In Ph-pos patients, OS improved in all age groups. This reflects not only the efficacy but also the good tolerance of TKI and low-dose chemotherapy suitable for older patients. 12, 14, 39 In our previously detailed study of elderly patients from this cohort, similar outcome was seen in Ph-pos ALL whether they were transplanted in CR1 or not at all. 21 In the EBMT Registry, OS was also comparable in younger Ph-pos patients regardless if they had undergone allogeneic or autologous HSCT. with TKI but not eligible for HSCT. 41 Yet, follow-up in relation to normal life expectancy is relatively short and robust long-term results are lacking. In our study, although 5-year OS improved in the youngest age group, a plateau in the survival curve was seen only at that time, a finding that might be attributed to graft-versus-leukaemia effect in transplanted patients. We still await a randomised trial that supports cure with chemotherapy and TKI without detrimental late effects or TKI-resistant relapses. A cautious interpretation could be that since HSCT is recommended for high-risk patients, the treatment seems to counterbalance the As we noticed in our previous study of older patients, 21 there was a pronounced difference in outcome between men and women in the Ph-neg B-ALL cohort of patients 46-65 years, which we now confirm in a larger cohort and over a longer period. Inferior prognosis for males was previously reported from Poland and in historical childhood cohorts. 47, 48 No explanation has emerged, and it is unclear whether this effect is due to the Swedish protocol ABCDV, male body mass, comorbidities or other unknown factors. Because of this and the insufficient long-term survival in all middle-aged patients,
we have introduced a dose-adjusted paediatric NOPHO 2008 protocol for Ph-neg patients >45 years without an upper chronological age limit but biological age approaching 65 years. 10 The present study provides important information on nationwide standard of care, where the nearly complete coverage of reported patients compared with the compulsory cancer registry adds strength to the material. Consequently, the selection bias was reduced, which is of particular importance regarding the elderly patients that are often excluded from randomised trials. The completeness of the diagnostic forms including descriptive data was high, and the Swedish social security number system makes OS undisputable. To further secure data accuracy, we confirmed and collected Ph status at the genetic laboratories. Nevertheless, diagnostic procedures have changed over time and were not centrally reviewed or certified and all patients were not properly evaluated. Being a registry-based database, the study depends on the accuracy of the registry forms. From a previous detailed study of older patients from this cohort, the frequency of patients with diagnosis incorrectly registered (as lymphoblastic lymphoma or lymphatic blast crisis in chronic myelogenous leukaemia) was approximately 5%. 21 In addition, outside randomised trials dubious diagnosis or results need to be considered and "exclusion criteria" do not exist, which leads to less stringent patient cohorts. It should also be noted that despite the high coverage and quality of vital status in the present and similar studies, follow-up reports including HSCT and relapses are likely to be incomplete, limiting more profound analyses of, for istrating the ALL quality registry, and last but not least, we thank all colleagues reporting to the registry.
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